Simon Ducharme
Distinguished in Developmental Dysphasia Familial

Dr. Simon Ducharme

1033 Pine Avenue West, 
Montreal, QC, CA 
Distinguished in Developmental Dysphasia Familial
1033 Pine Avenue West, 
Montreal, QC, CA 
OverviewLocationsClinical Research

Overview

Simon Ducharme practices in Montreal, Canada. Dr. Ducharme and is rated as a Distinguished provider by MediFind in the treatment of Developmental Dysphasia Familial. His top areas of expertise are Frontotemporal Dementia, Dementia, Developmental Dysphasia Familial, and Alzheimer's Disease.

His clinical research consists of co-authoring 170 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 21 articles and participated in 2 clinical trials in the study of Developmental Dysphasia Familial.

Licenses
Student in an Organized Health Care Education/Training Program in ZZ
Languages Spoken
English
Gender
Male

Locations

1033 Pine Avenue West, Montreal, QC H3A1A1, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia
A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drug: Syntocinon
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
Enrollment Status: Terminated
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: WVE-004
Study Phase: Phase 1/Phase 2
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression
Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression
Enrollment Status: Terminated
Publish Date: April 01, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

170 Total Publications

Prevalence and Features of Misdiagnosis of Primary Psychiatric Disorders Among bvFTD Patients.
Prevalence and Features of Misdiagnosis of Primary Psychiatric Disorders Among bvFTD Patients.
Journal: The Journal of neuropsychiatry and clinical neurosciences
Published: April 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ducharme's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile